Drug profile · INN
ozanimod hydrochloride
ZEPOSIA
ozanimod hydrochloride (ZEPOSIA) is a sphingosine 1-phosphate receptor edg-1 modulator. Route of administration: oral. Current US regulatory status: approved.
Drug details — ozanimod hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
ozanimod hydrochloride (ZEPOSIA) is a sphingosine 1-phosphate receptor edg-1 modulator. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Sphingosine 1-phosphate receptor Edg-1 modulator
Primary target: Sphingosine 1-phosphate receptor 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is ozanimod hydrochloride?
ozanimod hydrochloride (ZEPOSIA) is a sphingosine 1-phosphate receptor edg-1 modulator. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for ozanimod hydrochloride?
ZEPOSIA is a marketed brand name for ozanimod hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ozanimod hydrochloride?
ozanimod hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.